¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high purified insulin"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin-dependent diabetes
    Àν¶¸°ÀÇÁ¸´ç´¢º´
  • insulin-induced hypoglycemia
    Àν¶¸°À¯µµÀúÇ÷´ç(Áõ)
  • insulin-like activity
    Àν¶¸°À¯»çȰ¼ºµµ
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • insulin-resistant diabetes
    Àν¶¸°ÀúÇ×´ç´¢º´
  • insulin-to-glucose ratio
    Àν¶¸°´ëÆ÷µµ´çºñ
  • intermediate-acting insulin
    Áß°£ÀÛ¿ëÀν¶¸°
  • long acting insulin
    Áö¼ÓÀÛ¿ëÀν¶¸°
  • non-insulin-dependent diabetes
    ºñÀν¶¸°ÀÇÁ¸´ç´¢º´
  • NPH insulin
    NPHÀν¶¸°
  • regular insulin
    ¼ÓÈ¿Àν¶¸°, ºü¸¥ÀÛ¿ëÀν¶¸°
  • suppressive insulin
    ¾ïÁ¦Àν¶¸°
  • short acting insulin
    ´Ü±âÀÛ¿ëÀν¶¸°
  • high altitude
    °íÁö-, °í¼Ò-
  • high altitude illness
    °í¼Òº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin shock
    Àν¶¸°¼îÅ©
  • insulin sensitivity index
    Àν¶¸°°¨¼ºÁö¼ö
  • insulin-to-glucose ratio
    Àν¶¸°Æ÷µµ´çºñÀ²
  • long acting insulin
    Áö¼ÓÀν¶¸°
  • short acting insulin
    ´Ü±âÀÛ¿ëÀν¶¸°
  • suppressive insulin
    ¾ïÁ¦Àν¶¸°
  • high power application
    °íÃâ·ÂÀû¿ë
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ
  • high speed core cut biopsy
    °í¼ÓÁ߽ɻý°Ë
  • high frequency current
    °íÁÖÆÄÀü·ù
  • high polymer chemistry
    °íºÐÀÚÈ­ÇÐ
  • high-performance liquid chromatography
    °íÀÛÀ§¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-pressure liquid chromatography
    °í¾Ð·Â¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin sensitivity
    Àν¶¸°°¨(¼ö)¼º.
  • insulin sensitivity index
    Àν¶¸°°¨¼ºÁö¼ö.
  • insulin sensitivity test
    Àν¶¸°°¨¼º½ÃÇè.
  • insulin shock
    Àν¶¸°¼ï.
  • insulin shock therapy
    Àν¶¸°¼ï¿ä¹ý.
  • insulin shock treatment
    Àν¶¸°Ãæ°ÝÄ¡·á.
  • insulin test
    Àν¶¸°½ÃÇè.
  • insulin therapy
    Àν¶¸°Ä¡·á, Àν¶¸°¿ä¹ý.
  • insulin tolerance
    Àν¶¸°³»¼º.
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè.
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè
  • protamin insulin(e)
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) insulin
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • immunoreactive insulin =IRI
    ¸é¿ª¹ÝÀÀ¼º(¡­Úãëëàõ) Àν¶¸°.
  • insulin
  • insulin antagonist
    Àν¶¸°±æÇ×ü.
  • insulin antagonist
    Àν¶¸°±æÇ×Á¦.
  • insulin antiserum
    Ç×Àν¶¸°Ç÷û.
  • insulin coma therapy
    Àν¶¸° È¥¼ö Ä¡·á
  • insulin convulsive therapy combined
    Àν¶¸°°æ·Ãº´ÇÕÄ¡·á<¿ä¹ý>
  • insulin convulsive therapy combined
    Àν¶¸°°æ·Ãº´ÇÕÄ¡·á<¿ä¹ý>.
  • insulin deficiency diabetes
    Àν¶¸°°áÇ̼º ´ç´¢º´.
  • insulin dependence
    Àν¶¸°ÀÇÁ¸¼º.
  • insulin dependent diabetes mellitus =IDDM
    Àν¶¸°ÀÇÁ¸¼º ´ç´¢º´.
  • insulin edema
    Àν¶¸°ºÎÁ¾(¡­Ý©ðþ).
  • insulin like activity =ILa
    Àν¶¸°¾çȰ¼º(ÀÛ¿ë).
  • insulin lipodystrophy
    Àν¶¸°Áö¹æÀÌ¿µ¾çÁõ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • NPH insulin
    NPH Àν¶¸°
  • protamine zinc insulin
    ÇÁ·ÎŸ¹Î ¾Æ¿¬(䬿ç) Àν¶¸°
  • suppressible insulin-like activity
    ¾ï¾Ð °¡´É(åääâʦÒö) Àν¶¸°À¯»çȰ¼º(×¾ÞÄüÀàõ)
  • familial high-density lipoprotein deficiency °¡Á·¼º °í¹Ðµµ ÁöÁú´Ü¹éÁú °áÇÌ (Ê«ðéàõÍÔÚËÓøò·òõ
    Ó±ÛÜòõÌÀù¹)
  • high-density lipoprotein
    °í¹Ðµµ ÁöÁú´Ü¹éÁú(ÍÔÚËÓøò·òõÓ±ÛÜòõ)
  • high-energy bond
    °í(ÍÔ)¿¡³ÊÁö °áÇÕ(Ì¿ùê)
  • high-energy compound
    °í(ÍÔ)¿¡³ÊÁö È­ÇÕ¹°(ûùùêÚª)
  • high-energy ion scattering
    °í(ÍÔ)¿¡³ÊÁö À̿»ê¶õ(ߤկ)
  • high-energy phosphate donor
    °í(ÍÔ)¿¡³ÊÁö ÀÎ»ê°ø¿©ÀÚ(×òß«Íêæ¨í­)
  • high-level promoter
    °íÀ§(ÍÔêÈ)ÇÁ·Î¸ðÅÍ
  • high-lipid lipoprotein
    °íÁöÁú ÁöÁú´Ü¹éÁú(ÍÔò·òõò¢òõÓ±ÛÜòõ)
  • high-mannose glycoproteins
    ´Ù(Òý)¸¸³ë½º ´ç´Ü¹éÁú(ÓØÓ±ÛÜòõ)
  • high-mannose oligosaccharides
    ´Ù(Òý)¸¸³ë½º °ú´çÁú(ÍûÓØòõ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • high-performance liquid chromatography
    °í¼º´É(ÍÔàõÒö) ¾×ü(äûô÷) Å©·Î¸¶Åä±×·¡ÇÇ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high resolution computed tomography [=HRCT]
    °íÇØ»óÀü»êÈ­´ÜÃþÃÔ¿µ¼ú
  • high risk group
    °íÀ§Çèµµ±º
  • high signal
    °í½ÅÈ£
  • high signal intensity
    °í½ÅÈ£°­µµ
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high speed
    °í¼ÓÀÇ
  • high speed core cut biopsy
    °í¼ÓÁ߽ɻý°Ë
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • high voltage radiography
    °í¾ÐÃÔ¿µ¼ú
  • high voltage radiography
    °íÀü¾ÐÃÔ¿µ¼ú
  • HRCT [=high resolution comnputed tomography]
    °íÇØ»óÀü»êÈ­´ÜÃþÃÔ¿µ¼ú
  • paramagnetic high susceptibility
    »óÀÚ¼º°íÀÚÈ­À²
  • pseudodiastole in high intensity proton flow
    °í°­µµ¾çÀÚÀ¯µ¿¿¡¼­ À§À̿ϱâ
  • super high field MR scanner
    ÃʰíÀÚÀåMR½ºÄ³³Ê, ÃʰíÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • ultra high field MR scanner
    ÃʰíÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HPLC high-performance liquid chromatography; high-power liquid chromatography; high-pressure liquid chrom...
HT Hashimoto thyroiditis; hearing test; hearing threshold; heart; heart transplantation, heart transpla...
PPDs (Tuberculin) Purified Protein Derivatives
PAP pancreatitis-associated protein; Papanicolaou [test]; papaverine; passive-aggressive personality; pa...
PCW pericanalicular web; personal care worker; primary capillary wedge; pulmonary capillary wedge; purif...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PVRV Purified Vero cell rabies vaccine
AIR Acute insulin response
AIRg Acute insulin response to glucose
BHI Biosynthetic Human Insulin
IGF-1 C--insulin-like growth factor-1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • high condylectomy
    °í °úµÎ ÀýÁ¦¼ú, »ó°úµÎ ÀýÁ¦¼ú
    »ó,ÇÏ¾Ç °úµÎÀÇ ÀϺκи¸À» ¿Ü°úÀûÀ¸·Î Á¦°ÅÇÏ´Â °Í.
  • high copper amalgam
    °íµ¿ ¾Æ¸»°¨
    ¾Æ¸»°¨ Çձݿ¡¼­ ±¸¸®ÀÇ ºñ°¡ ³ôÀº °Í.
  • high dose tolerance
    °í¿ª ¿ªÄ¡
  • high electron density
    °íÀüÀÚ ¹Ðµµ
    ÀüÀÚµéÀÇ ¹Ðµµ°¡ ³ôÀº °÷.
  • high energy phosphate bond
    °í¿¡³ÊÁö ÀÎ»ê °áÇÕ
    ÀÎ»ê °áÇÕ ÇüŰ¡ ³ôÀº ¿¡³ÊÁö·Î ÀÌ·ç¾îÁø »óÅÂ. ÀÌ °áÇÕÀº ¾Æ³×³ë½Å »ïÀλê. Æ÷½ºÆ÷Å©·¹¾ÆÆ¾. ´ç ´ë»çÀÇ Áß°£»ê¹° µî¿¡ Á¸ÀçÇÑ´Ù.
  • high energy radiation
    °í¿¡³ÊÁö ¹æ»ç¼±
    ³ôÀº ¿¡³ÊÁöÀÇ ¹æ»ç¼±À» ¹æÃâÇÏ´Â °Í.
  • high fever
    °í¿­
    ³ôÀº ¿­.
  • high frequency
    °íºóµµ, °íÁÖÆÄ
    ¿¡³ÊÁö°¡ ÀÚÁÖ ¹ß»ýµÇ´Â °Í. ºóµµ°¡ ³ôÀº °Í.
  • high frequency heating
    °íÁÖÆÄ °¡¿­
  • high frequency wave
    °íÁÖÆÄ
  • high intensity proton flow
    °í°­µµ ¾çÀÚÀ¯µ¿
  • high lip line
    »ó¼ø¼±
    À­ ÀÔ¼úÀÇ À§ÂÊ °æ°è.
  • high pain threshold
    °í µ¿Åë ¿ªÄ¡
    ÅëÁõÀ» À¯¹ßÇØ ¹ÝÀÀÀ» ÀÏÀ¸Å°°Ô ÇÏ´Â ÃÖ¼ÒÇÑÀÇ ÀÚ±ØÀÇ °­µµ°¡ ³ôÀº °Í.
  • high power application
    °íÃâ·Â Àû¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
globin zinc insulin A sterile solution of insulin modified by the addition of zinc chloride and globin; it contains 40 or 80 units per ml; duration of action is about 18 hours.
Human insulin, a protein that has the normal structure of insulin produced by the human pancreas, prepared by recombinant DNA techniques and by semisynthetic processes.
Immunoreactive insulin (IRI), that portion of insulin in blood measured by immunochemical methods for the hormone; presumed to represent the free (unbound) and biologically active fraction of total blood insulin.
Isophane insulin, a modified form of insulin composed of insulin, protamine, and zinc; an intermediately acting preparation used for the treatment of diabetes mellitus.
Synonym: NPH insulin.
(05 Mar 2000)
crystalline insulin zinc suspension A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours.
Synonym: crystalline insulin zinc suspension.
(05 Mar 2000)
prompt insulin zinc suspension Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
protamine zinc insulin Insulin modified by the addition of protamine and zinc chloride; it contains 40 or 80 units per ml.
(05 Mar 2000)
semilente insulin Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
non-insulin-dependent diabetes mellitus <disease> An often mild form of diabetes mellitus of gradual onset, usually in obese individuals over age 35; absolute plasma insulin levels are normal to high, but relatively low in relation to plasma glucose levels; ketoacidosis is rare, but hyperosmolar coma can occur; responds well to dietary regulation and/or oral hypoglycaemic agents, but diabetic complications and degenerative changes can develop.
(05 Mar 2000)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
NPH insulin isophane insulin
diabetes mellitus, insulin-dependent Diabetes mellitus characterised by insulin deficiency, sudden onset, severe hyperglycaemia, rapid progression to ketoacidosis, and death unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
(12 Dec 1998)
diabetes mellitus, non-insulin-dependent Diabetes characterised by the ability to survive without ketoacidosis in the absence of insulin therapy. It is usually of slow onset and patients exhibit a tendency to obesity.
(12 Dec 1998)
insulin <drug, growth factor, hormone> A polypeptide hormone (bovine insulin, 5780D) found in both vertebrates and invertebrates.
Secreted by the _ cells of the pancreas in response to high blood sugar levels, it induces hypoglycaemia. Defective secretion of insulin is the cause of diabetes mellitus. Insulin is also a mitogen, has sequence homologies with other growth factors and is a frequent addition to cell culture media for demanding cell types.
(18 Nov 1997)
insulin activating factor <chemical> Activates insulin gene transcription in pancreatic beta cells.
Synonym: insaf
(05 Dec 1998)
insulin allergy When a person's body has an allergic or bad reaction to taking insulin made from pork or beef or from bacteria, or because the insulin is not exactly the same as human insulin or because it has impurities. The allergy can be of two forms. Sometimes an area of skin becomes red and itchy around the place where the insulin is injected. This is called a local allergy. In another form, a person's whole body can have a bad reaction. This is called a systemic allergy. The person can have hives or red patches all over the body or may feel changes in the heart rate and in the rate of breathing. A doctor may treat this allergy by prescribing purified insulins or by desensitisation.
See: desensitisation.
(09 Oct 1997)
insulin antagonist Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin.
(09 Oct 1997)
insulin-antagonizing factor A principle in extracts of the anterior lobe of the hypophysis that raises the blood sugar and antagonises the action of insulin; purified pituitary growth hormone produces an identical effect.
Synonym: insulin-antagonizing factor.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Middle High German
    Áß¼¼(Áß±â) °íÁö µ¶ÀϾî(12-15¼¼±â)
  • Old High German
    =GERMAN
  • contact high
    °¨¿°(°£Á¢) µµÃë(¸¶¾àµµÃëÀÚ¿Í Á¢Çϰųª ¿¬±â³¿»õ·Î ÃëÇϱâ)
  • extremely high frequency
    (Åë½Å)ÃʰíÁÖÆÄ
  • high
    ³ôÀº;...ÀÇ ³ôÀÌÀÇ;³ôÀº °÷(À¸·ÎºÎÅÍ)ÀÇ;°íÁöÀÇ;°í±Í(°í»ó,¼þ°í)ÇÑ;°í¿øÀÇ;°íÀ§ÀÇ;°í±ÞÀÇ;°ªºñ½Ñ;°Ý·ÄÇÑ;±ØµµÀÇ;°ú°ÝÇÑ;£Àº
  • high
    (¿¬°áÇü)(~³ôÀÌÀÇ)ÀÇ ¶æ
  • high Church
    °í±³È¸ÆÄ(¿µ±¹ ±³È¸ÆÄ Áß,±³È¸ÀÇ ±³ÀÇ ¹× ÀǽÄÀ» Á¸ÁßÇÏ´Â ÇÑÆÄ)
  • high Churchman
    °í±³È¸ÆÄ ½Åµµ
  • high Court
    °íµî¹ý¿ø
  • high German
    GERMAN
  • high Mass
    (Ä«Å縯) Àå¾öÇÑ ¹Ì»ç
  • high Strung
    Å«°Å¸®;Á߽ɰ¡
  • high altar
    (±³È¸´çÀÇ)ÁÖ Á¦´Ü;Áß¾Ó Á¦´Ü
  • high analysis
    (ºñ·á°¡)½Ä¹°ÀÇ ÇÊ¿ä ¾çºÐÀÇ 20% ÀÌ»óÀ» ÇÔÀ¯ÇÏ´Â
  • high atmospheric pressure
    °í±â¾Ð
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á